Interstitial lung disease (ILD) represents a diverse group of disorders characterized by infiltration of lung parenchyma with extracellular matrix, leading to progressive respiratory impairment and ...

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders ...

We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look ...

Investors might want to bet on MAIA Biotechnology, Inc. (MAIA), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential ...

In Bengaluru's Yelahanka area, a makeshift laboratory was the nucleus of chef Maia Laifungbam’s brand new experiment to recreate sake, or Japanese rice wine, in India. In the last few months ...

Chicago-based Maia Biotechnology said this week that its lead drug candidate, THIO, has gained its generic name, and preclinical data on a different form of the cancer drug suggests it could ...

MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, announced that the United States Adopted Names (USAN) Council has approved ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company valued at $48.94 million, has announced the publication of promising preclinical data for its ...